Impact of IL1RN Variants on Response to Interleukin‐1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis
نویسندگان
چکیده
منابع مشابه
Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy
Systemic-onset juvenile idiopathic arthritis (SJIA) is a disease of unknown etiology with an unpredictable response to treatment. We examined two groups of patients to determine whether there are serum protein profiles reflective of active disease and predictive of response to therapy. The first group (n = 8) responded to conventional therapy. The second group (n = 15) responded to an experimen...
متن کاملR202Q Mutation of Mediterranean Fever Gene in Iranian patients with Systemic-onset Juvenile Idiopathic Arthritis
Background: Systemic-onset Juvenile Idiopathic Arthritis (SoJIA) is an autoinflammatory disease with complex genetic trait starts in children less than 16 years of age with fever and cutaneous rash. Despite, the main genetic factors that may play a role in SoJIA have not yet been identified. High level of interleukin-1beta in the blood of SoJIA patients has been reported. The production and sec...
متن کاملImpact of juvenile idiopathic arthritis on schooling
BACKGROUND Juvenile idiopathic arthritis (JIA) is the most common arthropathy of childhood. Different diseases affect school attendance to varying degrees. The aim of this study was to assess the impact of juvenile idiopathic arthritis (JIA) on Moroccan children's schooling. METHODS Thirty-three children with JIA were included in this study, having been previously diagnosed according to the c...
متن کاملRituximab therapy for refractory systemic-onset juvenile idiopathic arthritis.
Systemic-onset juvenile idiopathic arthritis (SOJIA), formerly called Still’s disease, is a subset of juvenile arthritis that describes patients with fever, rash, arthritis, serositis and visceromegaly. In up to 30% of cases the disease has a chronic course and management requires high doses of glucocorticoids, disease-modifying antirheumatic drugs (DMARD), tumour necrosis factor alpha (TNFa) i...
متن کاملLeflunomide in systemic onset Juvenile idiopathic arthritis.
Methotrexate, the mainstay of treatment in Juvenile idiopathic arthritis, might not be effective in a few patients of polyarticular and systemic onset juvenile idiopathic arthritis. Use of biologicals like TNF-a blockers, the next line of preferred drugs is constrained by the high cost. We successfully used leflunomide in four patients.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arthritis & Rheumatology
سال: 2020
ISSN: 2326-5191,2326-5205
DOI: 10.1002/art.41130